Kiora Pharmaceuticals Inc. [NASDAQ: KPRX] gained 93.18% on the last trading session, reaching $1.70 price per share at the time. The company report on December 15, 2021 that Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors.
Salt Lake City, Utah–(Newsfile Corp. – December 15, 2021) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) announced the appointment of David Hollander, MD, MBA, to its Board of Directors. Dr. Hollander, who currently serves as the Chief Research and Development Officer of Aerie Pharmaceuticals, Inc. (“Aerie”), brings extensive ophthalmic industry expertise and insight to the Company’s board.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
“Kiora has a compelling development pipeline, including KIO-301, a clinical-ready small molecule with the potential to restore vision in patients with Retinitis Pigmentosa, a rare, genetic form of blindness,” said Dr. Hollander. “Further, the recently reported topline KIO-101 data suggest that Kiora has a differentiated compound, which could offer physicians a new first-in-indication option to treat dry eye disease by inhibiting T-cell proliferation and proinflammatory cytokines release. The Company’s development program is rounded out by KIO-201, intended to accelerate ocular wound healing and is in late-stage clinical development.”.
Kiora Pharmaceuticals Inc. represents 10.27 million in outstanding shares, while the company has a total market value of $21.74 million with the latest information. KPRX stock price has been found in the range of $1.04 to $1.7299.
If compared to the average trading volume of 995.48K shares, KPRX reached a trading volume of 117508652 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Kiora Pharmaceuticals Inc. [KPRX]:
The Average True Range (ATR) for Kiora Pharmaceuticals Inc. is set at 0.19, with the Price to Sales ratio for KPRX stock in the period of the last 12 months amounting to 1803.05. The Price to Book ratio for the last quarter was 1.01, with the Price to Cash per share for the same quarter was set at 0.87.
Trading performance analysis for KPRX stock
Kiora Pharmaceuticals Inc. [KPRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 92.94. With this latest performance, KPRX shares gained by 12.58% in over the last four-week period, additionally sinking by -54.55% over the last 6 months – not to mention a drop of -65.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KPRX stock in for the last two-week period is set at 68.34, with the RSI for the last a single of trading hit 78.70, and the three-weeks RSI is set at 60.99 for Kiora Pharmaceuticals Inc. [KPRX]. The present Moving Average for the last 50 days of trading for this stock 1.4738, while it was recorded at 1.0439 for the last single week of trading, and 2.8702 for the last 200 days.
Kiora Pharmaceuticals Inc. [KPRX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Kiora Pharmaceuticals Inc. [KPRX] shares currently have an operating margin of -68104.78. Kiora Pharmaceuticals Inc.’s Net Margin is presently recorded at -67102.91.
Return on Total Capital for KPRX is now -116.76, given the latest momentum, and Return on Invested Capital for the company is -116.13. Return on Equity for this stock declined to -118.81, with Return on Assets sitting at -64.04. When it comes to the capital structure of this company, Kiora Pharmaceuticals Inc. [KPRX] has a Total Debt to Total Equity ratio set at 5.17. Additionally, KPRX Total Debt to Total Capital is recorded at 4.92, with Total Debt to Total Assets ending up at 2.39. Long-Term Debt to Equity for the company is recorded at 4.48, with the Long-Term Debt to Total Capital now at 4.26.
Reflecting on the efficiency of the workforce at the company, Kiora Pharmaceuticals Inc. [KPRX] managed to generate an average of -$577,996 per employee. Receivables Turnover for the company is 0.25 with a Total Asset Turnover recorded at a value of 0.00.Kiora Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.10 and a Current Ratio set at 6.10.
An analysis of insider ownership at Kiora Pharmaceuticals Inc. [KPRX]
There are presently around $1 million, or 17.90% of KPRX stock, in the hands of institutional investors. The top three institutional holders of KPRX stocks are: GEODE CAPITAL MANAGEMENT, LLC with ownership of 237,477, which is approximately 1502.085% of the company’s market cap and around 1.30% of the total institutional ownership; VANGUARD GROUP INC, holding 151,702 shares of the stock with an approximate value of $0.13 million in KPRX stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $45000.0 in KPRX stock with ownership of nearly New of the company’s market capitalization.
Positions in Kiora Pharmaceuticals Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 12 institutional holders increased their position in Kiora Pharmaceuticals Inc. [NASDAQ:KPRX] by around 424,814 shares. Additionally, 6 investors decreased positions by around 3,598,876 shares, while 8 investors held positions by with 3,427,107 shares. The mentioned changes placed institutional holdings at 596,583 shares, according to the latest SEC report filing. KPRX stock had 8 new institutional investments in for a total of 177,188 shares, while 6 institutional investors sold positions of 3,598,876 shares during the same period.